Company profile: PaxVax
1.1 - Company Overview
Company description
- Provider of candidate oral vaccines for influenza and other key infectious diseases, using a proprietary adenovirus-based oral vaccine technology that addresses delivery hurdles of traditional injectable vaccines, including the need for cold storage and needles.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PaxVax
Chembio Diagnostics
HQ: United States
Website
- Description: Provider of proprietary rapid point-of-care diagnostic tests, developing, manufacturing, licensing and marketing DPP assays for HIV 1/2, HIV-Syphilis, Zika (IgM/IgG in Europe; IgM in the USA), Ebola antigen (USA), and Zika-Chikungunya-Dengue (Europe). Portfolio includes two FDA PMA-approved, CLIA-waived rapid HIV tests marketed in the U.S. by Alere (formerly Inverness Medical Innovations).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chembio Diagnostics company profile →
IncellDx
HQ: United States
Website
- Description: Provider of molecular diagnostics focused on detecting and monitoring life-threatening viral diseases, offering HPV OncoTect 3Dx assay quantifying E6/E7 mRNA for cervical cancer; incellKINE Long COVID in vitro diagnostic (CE marked); HPV E6/E7 mRNA probe; CMV mRNA probe (RUO); hybridization core reagents; and HPV control cells (RUO).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IncellDx company profile →
AiCuris
HQ: Germany
Website
- Description: Provider of resistance breaking antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, hepatitis B and C, and multi-resistant bacteria; offerings include PREVYMIS for CMV prevention in adult CMV-seropositive allogeneic stem cell or kidney transplant recipients, pritelivir (phase 3) for acyclovir-resistant HSV, AIC468 (preclinical) for BK virus, adenovirus treatment programs, and the AiCubator for early-stage research on viral infections in immunocompromised patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCuris company profile →
Lumos Diagnostics
HQ: United States
Website
- Description: Provider of rapid point-of-care diagnostic solutions, including customized assay development, full-scale contract manufacturing for lateral flow strips and readers, proprietary digital reader platforms, companion apps, and cloud connectivity for data capture and visualization, supported by in-house clinical study design, site management, and regulatory affairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumos Diagnostics company profile →
Pharmasset
HQ: United States
Website
- Description: Provider of novel oral therapeutics to treat viral infections, with a primary focus on hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Clinical-stage pharmaceutical company committed to discovering, developing, and commercializing antiviral drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmasset company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PaxVax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PaxVax
2.2 - Growth funds investing in similar companies to PaxVax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PaxVax
4.2 - Public trading comparable groups for PaxVax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →